Active Ingredient: Eltrombopag
Eltrombopag is indicated in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation.
For this indication, competent medicine agencies globally authorize below treatments:
Oral
25 - 150 mg
From 25 To 150 mg once every day
Eltrombopag should be initiated at a dose of 50 mg once daily. For patients of Asian ancestry, eltrombopag should be initiated at a reduced dose of 25 mg once daily. The treatment should not be initiated when the patients has existing cytogenetic abnormalities of chromosome 7.
Haematological response requires dose titration, generally up to 150 mg, and may take up to 16 weeks after starting eltrombopag. The dose of eltrombopag should be adjusted in 50 mg increments every 2 weeks as necessary to achieve the target platelet count ≥50,000/µl. For patients taking 25 mg once daily, the dose should be increased to 50 mg daily before increasing the dose amount by 50 mg. A dose of 150 mg daily must not be exceeded. Clinical haematology and liver tests should be monitored regularly throughout therapy with eltrombopag and the dosage regimen of eltrombopag modified based on platelet counts as outlined in the followinh table.
Dose adjustments of eltrombopag in patients with severe aplastic anaemia:
| Platelet count | Dose adjustment or response |
|---|---|
| <50.000/µl following at least 2 weeks of therapy | Increase daily dose by 50 mg to a maximum of 150 mg/day. For patients taking 25 mg once daily, increase the dose to 50 mg daily before increasing the dose amount by 50 mg. |
| ≥50.000/µl to ≤150.000/µl | Use lowest dose of eltrombopag to maintain platelet counts. |
| >150.000/µl to ≤250.000/µl | Decrease the daily dose by 50 mg. Wait 2 weeks to assess the effects of this and any subsequent dose adjustments. |
| >250.000/µl | Stop eltrombopag; for at least one week. Once the platelet count is ≤100,000/µl, reinitiate therapy at a daily dose reduced by 50 mg. |
For patients who achieve tri-lineage response, including transfusion independence, lasting at least 8 weeks: the dose of eltrombopag may be reduced by 50%.
If counts remain stable after 8 weeks at the reduced dose, then eltrombopag must be discontinued and blood counts monitored. If platelet counts drop to <30,000/µl, haemoglobin drops to <9 g/dl or absolute neutrophil count (ANC) <0.5 × 109/l, eltrombopag may be reinitiated at the previous effective dose.
If no haematological response has occurred after 16 weeks of therapy with eltrombopag, therapy should be discontinued. If new cytogenetic abnormalities are detected, it must be evaluated whether continuation of eltrombopag is appropriate. Excessive platelet count responses (as outlined in the above table) or important liver test abnormalities also necessitate discontinuation of eltrombopag.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
